3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
1
Conditions
Breast Neoplasms
10
Prostatic Neoplasms
7
Sarcoma
4
Uterine Cervical Neoplasms
3
Squamous Cell Carcinoma of Head and Neck
3
Pancreatic Neoplasms
3
Carcinoma, Intraductal, Noninfiltrating
3
Urinary Bladder Neoplasms
2
Lung Neoplasms
2
Endometrial Neoplasms
2
Cholangiocarcinoma
2
Carcinoma, Non-Small-Cell Lung
2
Breast Carcinoma In Situ
2
Urologic Neoplasms
1
Urologic Diseases
1
Urogenital Neoplasms
1
Urogenital Diseases
1
Urinary Bladder Diseases
1
Triple Negative Breast Neoplasms
1
Small Cell Lung Carcinoma
1
Sarcoma, Ewing
1
Prostate Adenocarcinoma
1
Pituitary Neoplasms
1
Neurilemmoma
1
Nerve Sheath Neoplasms
1
Neoplasms by Site
1
Neoplasms
1
Neoplasm Metastasis
1
Meningioma
1
Male Urogenital Diseases
1
Interventions
pembrolizumab
5
enfortumab vedotin
3
Gemcitabine
3
dodecyl maltoside
2
Sunitinib
2
Cisplatin
2
zidovudine 5'-monophosphate-mannose-albumin conjugate
1
tucatinib
1
testosterone 17 beta-cypionate
1
temsirolimus
1
relatlimab
1
palbociclib
1
niraparib
1
galactosamine-conjugated serum albumin-conjugated-(rhodamine X)20
1
cabozantinib
1
Valproic Acid
1
Urinary Diversion
1
Trastuzumab
1
Testosterone Propionate
1
Standard of Care
1
Sirolimus
1
Rivaroxaban
1
Ringer's acetate
1
Radiosurgery
1
Radiation Dose Hypofractionation
1
Psychiatric Nursing
1
Practice Guidelines as Topic
1
Physical Therapy Modalities
1
Nivolumab
1
Multiparametric Magnetic Resonance Imaging
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Urologic Neoplasms
×
Radiation Dose Hypofractionation
×
1 year
×
Clear all
NCT07566156
2026-05-11
EV-309
Astellas Pharma Inc
Phase 3
Recruiting
390 enrolled